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AbstrAct
This document represents the first position statement 
produced by the British Society of Gastroenterology 
and Association of Upper Gastrointestinal Surgeons 
of Great Britain and Ireland, setting out the minimum 
expected standards in diagnostic upper gastrointestinal 
endoscopy. The need for this statement has arisen 
from the recognition that while technical competence 
can be rapidly acquired, in practice the performance 
of a high- quality examination is variable, with an 
unacceptably high rate of failure to diagnose cancer at 
endoscopy. The importance of detecting early neoplasia 
has taken on greater significance in this era of minimally 
invasive, organ- preserving endoscopic therapy. In this 
position statement we describe 38 recommendations 
to improve diagnostic endoscopy quality. Our goal is to 
emphasise practices that encourage mucosal inspection 
and lesion recognition, with the aim of optimising the 
early diagnosis of upper gastrointestinal disease and 
improving patient outcomes.
IntroductIon 
Oesophago-gastro-duodenoscopy (OGD) is the 
gold standard test for the investigation of upper 
gastrointestinal (UGI) symptoms, allowing direct 
mucosal visualisation, tissue acquisition and when 
required, therapeutic intervention. Demand has 
been consistently increasing, with an estimated 
3000 OGDs performed per 250 000 popula-
tion annually.1 This figure is likely to increase 
further following the introduction of UGI cancer 
awareness campaigns.2 Certification of training 
and assessment of competence in the perfor-
mance of OGD is the remit of the Joint Advisory 
Group (JAG) on gastrointestinal endoscopy.3 The 
main focus of this process is on technical compe-
tence and procedural safety, with the ability to 
complete the examination without complications 
being the primary objective. A combination of a 
known average rate of failure to diagnose cancer 
at endoscopy of 11.6%, coupled with a paradigm 
shift towards detecting early cancers which may 
be potentially amenable to organ-preserving endo-
scopic therapy, has necessitated an improvement 
in quality.4–7 Following the institution of auditable 
measures, colonoscopy has experienced a signif-
icant improvement in quality. It is hoped that a 
similar implementation of standards can replicate 
this phenomenon in UGI endoscopy.
AIms And scope
The purpose of this position statement is to reduce 
variation in practice and standards between indi-
vidual endoscopists and units by establishing a set 
of auditable key performance indicators (KPIs). In 
particular, these recommendations aim to optimise 
the diagnosis of early neoplasia and premalignant 
conditions, in order to affect the natural history of 
UGI malignancies, which are currently associated 
with a poor prognosis due to late detection. These 
KPIs are aimed at all UGI endoscopists, who irre-
spective of background discipline should possess 
sufficient skill to perform a high-quality diagnostic 
OGD before independent practice. These KPIs 
have been written with standard OGD in mind, 
although it is recognised that alternative modalities 
are being explored, some of which are being used 
in parallel—for example, ultrathin transnasal video 
endoscopy. Where new technology is employed, 
quality should be maintained, even though tech-
nical capabilities may be different. Specific issues 
related to training, management of specific disease 
processes and unit management are beyond the 
scope of this position statement and have therefore 
not been discussed here.
Most of these recommendations have been 
designed to be measurable parameters, so that prac-
tice can be measured against them. It is expected 
that where there is a shortfall in meeting accepted 
targets, measures to improve quality should be insti-
tuted. This position statement was developed to 
provide guidance for endoscopists practising within 
the UK but, as with recent European guidelines, it is 
of international relevance.8
methodoloGy
This position statement was commissioned by the 
British Society of Gastroenterology (BSG) in asso-
ciation with the Association of UGI Surgeons of 
to cite: Beg S, Ragunath K, 
Wyman A, et al. Gut 
Published Online First: [please 
include Day Month Year]. 
doi:10.1136/
gutjnl-2017-314109
For numbered affiliations see 
end of article.
correspondence to
Professor Krish Ragunath, 
NIHR Nottingham Digestive 
Diseases Biomedical Research 
Centre, Queens Medical Centre 
campus, Nottingham University 
Hospitals NHS Trust, Nottingham 
NG7 2UH, UK;  k. ragunath@ 
nottingham. ac. uk
Received 31 March 2017
Revised 26 June 2017
Accepted 12 July 2017
 Gut Online First, published on August 18, 2017 as 10.1136/gutjnl-2017-314109
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& BSG) under licence. 
group.bmj.com on August 20, 2017 - Published by http://gut.bmj.com/Downloaded from 
2 Beg S, et al. Gut 2017;0:1–14. doi:10.1136/gutjnl-2017-314109
Guidelines
Great Britain (AUGIS) and was designed and written by a Guide-
line Development Group. This group was formed of 10 voting 
individuals, with representation across the relevant disciplines, 
including a surgical and a nursing representative. A UGI patholo-
gist specifically reviewed recommendations for tissue acquisition 
and interpretation.
Although this document is a position statement rather than a 
guideline, we aimed to adopt a similar level of methodological 
rigour and transparency as described by the Appraisal of Guide-
lines for Research and Evaluation II (AGREE II).9 On meeting, 
the Guideline Development Group identified factors that were 
deemed to be important in ensuring a high-quality UGI exam-
ination. Research questions were formulated using the PICO 
(Population, Intervention, Comparator, Outcome) framework, 
in order to guide a comprehensive search strategy.10 A comput-
erised literature search was performed using PubMed Medline, 
Embase and the Cochrane Library to identify original research 
papers, conference abstracts and existing guidelines, through 
to January 2016. Searches were limited to articles published 
in English. Review of the bibliographies of the identified clin-
ical studies was used to identify further relevant studies. The 
resultant body of evidence was reviewed and evaluated by all 
the members of the group, using the Grading of Recommenda-
tion Assessment, Development and Evaluation (GRADE) tool.9 
Where there was insufficient clinical evidence to support a state-
ment, recommendations were reached by expert consensus. Each 
member of the group voted on each statement, giving a level of 
agreement with each KPI using a five-point scale (1=strongly 
disagree to 5=strongly agree), with ≥80% agreement required 
for inclusion. Review of the evidence and initial voting was 
performed individually. Where consensus was not reached, 
statements were reviewed, modified and re-evaluated using the 
Delphi process, until there was sufficient agreement to either 
include or discard the statement.11 This process occurred via a 
combination of email, teleconference and face-to-face meetings 
over a 12-month period (figure 1).
The result of this process was a series of recommendations, 
with a corresponding level of expert agreement and grading 
of the relevant evidence (table 1). From these statements a 
smaller number of KPIs were selected following group discus-
sion. These were chosen based on the potential to influence 
patient outcomes as well as being both pragmatic and audit-
able. It is recognised that owing to the nature of some of the 
areas covered, there may be limited or weak evidence to support 
specific statements. Where a strong recommendation has been 
made despite weak evidence, this has been arrived at by expert 
consensus based on a pragmatic approach. These statements 
underwent peer review by the BSG Endoscopy Committee, 
AUGIS and the BSG Clinical Services and Standards Committee. 
In the majority we have indicated the acceptable target for 
achieving the measurable parameter, which should be subject to 
internal audit (table 2). A subset of these recommendations are 
by their nature either more difficult to measure or have been 
designed with current developments in endoscopy in mind, and 
therefore could be considered to be aspirational. Where eval-
uation of the literature has identified a paucity of evidence in 
areas pertinent to diagnostic OGD, we have proposed research 
questions, the answers to which may alter practice in the future. 
We have divided recommendations logically with respect to the 
patient pathway into:
 ► Preprocedure
 ► Procedure
 ► Disease specific
 ► Postprocedure.
preprocedure quality standards
Patients should be assessed for fitness to undergo a diagnostic 
OGD.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
An assessment of pre-existing conditions and medications 
should be made before performing an OGD. This can be inte-
grated into the booking-in process or within a preprocedure 
checklist to avoid duplication. Where changes to antiplatelet or 
anticoagulant therapy are indicated in accordance with existing 
guidelines, the management strategy should be both documented 
and communicated to the patient.12
Patients should receive appropriate information about the 
procedure, before undergoing an OGD.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
In order to be able to give informed consent, information 
about the proposed procedure and its associated risks must be 
explained.13 14 As the majority of OGDs are performed on an 
elective basis, information should be provided before the proce-
dure date, with an opportunity to ask questions.14 There is 
evidence that information can improve patient experience.15–19 
Combined written and oral information appears to be better 
understood than oral information alone, with little evidence for 
the use of videotaped information.20–22 Evidence suggests that 
patients prefer more information rather than less.23 However, 
it is noted that anxiety correlates with age and gender and may 
influence the way in which information is delivered.22 There is 
little to suggest who is best suited to delivering patient informa-
tion, but in most cases it would be expected to be the referrer 
proposing or arranging investigations.
An appropriate time slot should be allocated dependent on 
procedure indications and patient characteristics.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
It is recognised that the time taken to perform an OGD varies 
depending on indication, pathology and patient factors. Certain 
clinical indications—for example, the surveillance of premalig-
nant conditions, require careful inspection and possibly the use 
of advanced imaging and are therefore expected to take longer.24
In Barrett’s surveillance there is some evidence that a 
‘Barrett’s inspection time’ of >1 min/cm is associated with 
a significantly greater detection of high-grade dysplasia and 
adenocarcinoma.25 We would recommend that a standard 
diagnostic endoscopy is allocated a slot of a minimum of 
20 min, increasing as appropriate for surveillance or high-risk 
conditions.
Informed consent should be obtained before performing an 
OGD.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Obtaining informed consent from those with mental 
capacity is a legal requirement, as outlined in the General 
Medical Council’s document 'Consent guidance: legal frame-
work' and BSG's 'Guidance for obtaining valid consent for 
elective endoscopic procedures'.13 14 It is generally accepted 
that OGD involves a degree of risk and so written consent 
should be recorded. Those with adequate training and suffi-
cient knowledge of the procedure and potential complications 
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can obtain consent. Sending information and consent forms 
through the post, before the procedure may be a practical 
way of ensuring that patients have enough time to read and 
consider the required information.26 27 Where an absence of 
capacity has been demonstrated a decision about whether to 
perform an OGD in the patient's best interests should be made 
by a physician, preferably by the referrer.13
A safety checklist should be completed before starting an 
OGD.
Level of agreement: 100%
Figure 1 Flow chart of the statement development process. OGD, oesophago-gastro-duodenoscopy; PICO, Population, Intervention, Comparator, 
Outcome.
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Grade of evidence: moderate
Strength of recommendation: strong
There is a recognised serious complication rate of 3–16% 
associated with major surgery, of which half of these incidents 
are thought to be preventable. This triggered the introduction 
of a 20-point preoperative checklist, as part of the ‘Safe Surgery 
Saves Lives’ initiative.28 The use of this tool has been tested in 
a variety of surgical disciplines. More recently, variations of this 
tool have been adopted in higher-risk medical interventions, 
including endoscopy.29–33 There is no standardised endoscopy 
checklist, however, we recommend domains that should be 
checked before starting an OGD include31 34:
 ► patient identifiers (name/hospital number/date of birth)
 ► allergies
 ► medications/conditions that may preclude any interventions 
(anticoagulants)
table 1 A summary of the upper gastrointestinal endoscopy quality standards and associated strength of recommendation
summary of quality standards
Grade of 
evidence
strength of 
recommendation Agreement
Patients should be assessed for fitness to undergo a diagnostic OGD Weak Strong 100%
Patients should receive appropriate information about the procedure before undergoing an OGD Weak Strong 100%
An appropriate time slot should be allocated dependent on procedure indications and patient characteristics Weak Strong 100%
Informed consent should be obtained before performing an OGD Weak Strong 100%
A safety checklist should be completed before starting an OGD Moderate Strong 100%
A checklist should be undertaken after completing an OGD, before the patient leaves the room Weak Strong 90%
Only an endoscopist with appropriate training and the relevant competencies should independently perform OGD Weak Strong 100%
We suggest that endoscopists should aim to perform a minimum of 100 OGDs a year, to maintain a high-quality examination 
standard 
Weak Weak 100%
UGI endoscopy should be performed with high-definition video endoscopy systems, with the ability to capture images and take 
biopsies
Weak Strong 90%
Intravenous sedation and local anaesthetic throat spray can be used in conjunction if required. Caution should be exercised in 
those at risk of aspiration
Moderate Strong 100%
A complete OGD should assess all relevant anatomical landmarks and high-risk stations Weak Strong 100%
Photo-documentation should be made of relevant anatomical landmarks and any detected lesions Weak Strong 100%
The quality of mucosal visualisation should be reported. Weak Strong 100%
Adequate mucosal visualisation should be achieved by a combination of adequate air insufflation, aspiration and the use of 
mucosal cleansing techniques
Moderate Strong 100%
It is suggested that the inspection time during a diagnostic OGD should be recorded for surveillance procedures, such as Barrett’s 
oesophagus and gastric atrophy/intestinal metaplasia surveillance
Weak Weak 90%
Where a lesion is identified, this should be described using the Paris classification and targeted biopsies taken Weak Strong 100%
Endoscopy units should adhere to safe sedation practice Weak Strong 100%
The length of a Barrett’s segment should be classified according to the Prague classification Weak Strong 100%
Where a lesion is identified within a Barrett’s segment, this should be described using the Paris classification and targeted 
biopsies taken
Weak Strong 100%
When no lesions are detected within a Barrett’s segment, biopsies should be taken in accordance with the Seattle protocol Moderate Strong 90%
If squamous neoplasia is suspected, full assessment with enhanced imaging and/or Lugol’s chromo-endoscopy is required Moderate Strong 100%
Oesophageal ulcers and oesophagitis that is grade D or atypical in appearance, should be biopsied, with further evaluation in 
6 weeks after PPI therapy
Weak Strong 100%
The presence of an inlet patch should be photo-documented Weak Weak 90%
The presence of a hiatus hernia should be documented and measured Weak Weak 100%
Biopsies from two different regions in the oesophagus should be taken to rule out eosinophilic oesophagitis in those presenting 
with dysphagia/food bolus obstruction, where an alternate cause is not found
Moderate Strong 100%
Varices should be described according to a standardised classification Weak Strong 100%
Strictures should be biopsied to exclude malignancy before dilatation Weak Weak 90%
Gastric ulcers should be biopsied and re-evaluated after appropriate treatment, including H. pylori eradication where indicated, 
within 6–8 weeks
Weak strong 90%
Where there are endoscopic features of gastric atrophy or IM separate biopsies from the gastric antrum and body should be taken Weak Weak 100%
Where iron deficiency anaemia is being investigated, separate biopsies from the gastric antrum and body should be taken, as well 
as duodenal specimens if coeliac serology is positive or has not been previously measured 
Weak Weak 80%
Where gastric or duodenal ulcers are identified, H. pylori should be tested and eradicated if positive Moderate Strong 100%
The presence of gastric polyps should be recorded, with the number, size, location and morphology described, and representative 
biopsies taken
Moderate Strong 100%
Where coeliac disease is suspected, a minimum of four biopsies should be taken, including representative specimens from the 
second part of the duodenum and at least one from the duodenal bulb
Strong Strong 100%
A malignant looking lesion should be described, photo documented and a minimum of six biopsies taken Weak Strong 100%
After OGD readmission, mortality and complications should be audited Weak Strong 100%
A report summarising the endoscopy findings and recommendations should be produced and the key information provided to the 
patient before discharge
Weak Strong 100%
A method for ensuring histological results are processed must be in place Weak Strong 100%
Endoscopy units should audit rates of failing to diagnose cancer at endoscopy up to 3 years before an oesophago-gastric cancer 
is diagnosed
Weak Strong 100%
IM, intestinal metaplasia; OGD, oesophago-gastro-duodenoscopy; PPI, proton pump inhibitor.
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 ► significant comorbidities
 ► patient understanding of proposed test
 ► completion of a consent form.
A checklist should be undertaken after completing an OGD, 
before the patient leaves the room.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: strong
On completing an OGD, the following details should be 
reviewed and confirmed28:
 ► the number of histological samples taken
 ► the correct labelling of histological samples
 ► the dose of sedation and/or analgesia given
 ► any specific postprocedure advice to be given to the patient
 ► follow-up arrangements.
Procedure quality standards
Only an endoscopist with appropriate training and the relevant 
competencies should independently perform OGD.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
OGD training is though registration and certification via JAG.3 
To attain competence a minimum number of 200 diagnostic proce-
dures must be performed, before a summative assessment using 
a structured objective assessment tool.3 35 36 At present, although 
technical competence is assessed, lesion recognition is not a compo-
nent specifically assessed by the certification process. Lesions of the 
UGI tract are varied and may be subtle in nature, making quality 
difficult to measure objectively. We therefore propose that courses 
on lesion recognition and management form part of the continuing 
professional development of an UGI endoscopist.37
More experience in lesion recognition is likely to be required 
in high-risk and surveillance populations. With this in mind, 
service planning to ensure that patients at increased risk are allo-
cated to an endoscopist with the most relevant experience would 
be desirable. There is some evidence of increased dysplasia yields 
associated with dedicated Barrett’s lists.38 Where expertise is not 
available, referral to a tertiary centre should be considered.39
We suggest that endoscopists should aim to perform a 
minimum of 100 OGDs a year to maintain a high-quality exam-
ination standard.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: weak
It is our opinion that to be able to maintain the ability 
to perform a high-quality examination, OGDs should be 
performed regularly. There is no evidence to support a specific 
minimum number of procedures required to maintain profi-
ciency in OGD once an individual is deemed competent. There 
are data, mainly from the military and surgical specialties, that 
breaks in performing any given task results in a ‘skills decay’. 
The rate at which this occurs depends on the complexity of the 
task, the duration of the break and the level of previous compe-
tency achieved.40–44 In trainees it has been shown that a break 
in colonoscopy training results in a decline in competency.45 
We propose that endoscopists should aim for a minimum 
of 100 OGDs performed each year to ensure the ability to 
perform a high-quality diagnostic examination. We accept 
that some endoscopists perform a large number of therapeutic 
endoscopies in other aspects of endoscopy while undertaking 
relatively few diagnostic OGDs. These endoscopists should 
not be prevented from undertaking UGI endoscopy, but we 
table 2 The minimal expected achievement of upper gastrointestinal endoscopy key performance indicators
Quality indicator minimal standard
Aspirational 
standard
A minimum number of 100 OGDs per year should be performed to maintain competence Not applicable 100%
Photo documentation should be made of relevant anatomical landmarks Not applicable >90%
Photo documentation should be made of any detected lesions >90% 100%
Adequate mucosal visualisation should be achieved by a combination of both aspiration and the use of mucosal cleansing techniques 75% 100%
The quality of mucosal visualisation should be reported Not Applicable 90%
It is suggested that the inspection time during a diagnostic OGD should be recorded for surveillance procedures, such as Barrett’s and 
gastric atrophy/intestinal metaplasia surveillance
Not applicable >90%
Where a lesion is identified, this should be described using the Paris classification and targeted biopsies taken >90% 100%
The length of a Barrett’s segment should be classified according to the Prague classification >90% 100%
When no lesions are detected within a Barrett’s segment biopsies should be taken in accordance with the Seattle protocol >90% 100%
Biopsies from two different regions in the oesophagus should be taken to rule out eosinophilic oesophagitis in those presenting with 
dysphagia/food bolus obstruction, where an alternative cause is not found
>90% 100%
Oesophageal ulcers and oesophagitis that is grade D or atypical in appearance, should be biopsied, with further evaluation in 4–6 weeks 
of PPI therapy
>90% 100%
Gastric ulcers should be biopsied and re-evaluated after appropriate treatment, including H. pylori eradication where indicated, within 
6–8 weeks
>90% 100%
The presence of gastric polyps should be recorded, with the number, size, location and morphology described, with representative 
biopsies taken
>90% 100%
Where there are endoscopic features of gastric atrophy or intestinal metaplasia separate biopsies from the antrum and body should be 
taken
Not applicable >90%
Where iron deficiency anaemia is being investigated, separate biopsies from the gastric antrum and body should be taken as well as 
duodenal specimens if coeliac serology is positive or has not been previously measured 
Not applicable >90%
Where gastric or duodenal ulcers are identified, H. pylori should be tested and eradicated if positive >90% 100%
Where coeliac disease is suspected, a minimum of four biopsies from the second part of the duodenum including a specimen from the 
duodenal bulb should be taken
>90% 100%
Endoscopy units should audit rates of failing to diagnose upper gastrointestinal cancer at OGD <10% <5%
OGD, oesophago-gastro-duodenoscopy; PPI, proton pump inhibitor.
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recommend that their practice is audited as described in these 
standards.
UGI endoscopy should be performed with high-definition 
video endoscopy systems, with the ability to capture images and 
take biopsies.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: strong
All diagnostic OGDs should be performed with equipment 
capable of achieving the intended purpose. As a minimum, 
endoscopes with the capacity to produce high-definition 
images should be used. Equipment for obtaining adequate 
mucosal views and acquisition of histological samples should 
be available
A complete OGD should assess all relevant anatomical land-
marks and high-risk stations.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
In order to achieve a complete examination of the UGI tract, 
a standardised set of landmarks should be examined. The proce-
dure should start at the upper oesophageal sphincter and reach 
the second part of the duodenum, to include the upper oesoph-
agus, gastro-oesophageal junction, fundus, gastric body, incisura, 
antrum, duodenal bulb and distal duodenum. The fundus should 
be inspected by a J-manoeuvre in all patients, and where there 
is a hiatus hernia the diaphragmatic pinch should be inspected 
while in retroflexion.
Photo-documentation should be made of relevant anatomical 
landmarks and any detected lesions.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
While there is no evidence to support the practice of photo-doc-
umentation, it is intuitive that this practice encourages mucosal 
cleansing, mucosal inspection and ensures a complete examina-
tion. Beyond documentation, freezing an image offers the endos-
copist the opportunity to inspect an area of interest, without 
artefact caused by patient movement. Photo-documentation may 
also act as a legal record of an adequate/complete procedure. 
The  European Society of Gastrointestinal Endoscopy (ESGE) 
guidelines describe a systematic approach to photo-documenta-
tion (figure 2), with a recommendation of eight anatomical land-
marks.46 It is noted that countries that have a higher incidence 
of gastric cancers have adopted an even more rigorous approach 
to photo-documentation in order to optimise early diagnosis.47 
The widespread availability of electronic image capture systems 
makes this an achievable goal.48
The quality of mucosal visualisation should be reported.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
In order to be able to exclude early UGI lesions, it is neces-
sary to be able to inspect the mucosa, free of bubbles and 
debris. The quality of views obtained is not routinely stated, in 
contrast to the reporting of bowel preparation quality during 
colonoscopy. We propose that the quality of views obtained are 
rated according to a validated scale and recorded as part of the 
report.49–51 Where complete views are unattainable, this should 
be documented, with a recommendation of whether the proce-
dure requires repetition. Where patient agitation or intolerance 
precludes a complete examination, repeating the OGD with 
optimal sedation should be considered.
Adequate mucosal visualisation should be achieved by a 
combination of adequate air insufflation, aspiration and the use 
of mucosal cleansing techniques.
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
Clear mucosal views can be attained by aspirating debris and 
washing the mucosal surface by flushing water through the 
accessory channel of the endoscope. Mucosal cleansing can be 
made more convenient with the use of a pump-controlled water 
jet, which allows for the simultaneous use of accessories through 
the working channel. The addition of mucolytic and defoaming 
agents such as simethicone, N-acetylcysteine or pronase enables 
the dispersion of bubbles and mucous. Premedication with a 
swallowed mucolytic has been shown to reduce the need for 
washing between procedures and consequently procedure time, 
as well as appearing to offer superior mucosal views.50 52–59 The 
optimal timing for preprocedure consumption of these agents 
appears to be 10–30 min before and so could be incorporated 
into the admission process.58
It is suggested that the Inspection time during a diagnostic 
OGD should be recorded for surveillance procedures, such as 
Barrett’s oesophagus and gastric atrophy/intestinal metaplasia 
surveillance.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: weak
Despite the various tasks that require completion during an 
allocated endoscopy time slot, the time taken to perform the 
procedure itself should not be compromised. A high-quality 
examination, which includes mucosal cleansing and inspec-
tion, requires time. It is our opinion that a complete OGD 
begins after intubation of the upper oesophageal sphincter, then 
progresses to reach the distal duodenum before a careful with-
drawal and inspection starts. The whole procedure should take 
on average 7 min. A single study has demonstrated that endos-
copists taking on average of >7 min for an OGD had a three-
fold increase in the diagnosis of gastric cancer and dysplasia 
compared with those taking an average of <7 min to complete 
the procedure.24 Given the heterogeneity of patients presenting 
for OGD it is recognised that procedure times will vary. In order 
to move towards an optimally timed examination, an endosco-
pist should first be aware of the time spent on the examination. 
It is therefore our recommendation that the total inspection 
time for high-risk and surveillance procedures such as Barrett’s 
oesophagus or gastric atrophy surveillance is recorded and docu-
mented as part of the report.
Where a lesion is identified, this should be described using the 
Paris classification and targeted biopsies taken.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Universal language in reporting aids decision-making, and 
thus we would recommend that the morphology of a detected 
lesion is described according to the Paris classification, with the 
anatomical location described.60 Photo-documentation should 
be obtained and targeted biopsy specimens acquired as appro-
priate.61
Endoscopy units should adhere to safe sedation practice.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
It is recognised that in some patients a high-quality 
examination may be possible only using sedation and/or 
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analgesia.62 63 Endoscopy units should adhere to pre-existing safe 
sedation guidelines.64–66 This involves ensuring sedation is given 
with age and comorbidities in mind, and with appropriate moni-
toring.67–70 Any occasion where naloxone, flumazenil or ventila-
tion is required owing to oversedation should be recorded and 
investigated. An internal audit of sedation-related complications 
and the frequency that sedation is used outside of recommended 
guidelines, should take place as described by JAG.3
Intravenous sedation and local anaesthetic throat spray can be 
used in conjunction if required. Caution should be exercised in 
those at risk of aspiration. 
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
There is concern that sedation used in combination with topical 
anaesthesia increases the likelihood of aspiration pneumonia and 
postprocedure complications.71–74 Several studies have shown 
that this combination can improve tolerance and comfort of an 
OGD.75–82 There is a paucity of evidence as to an increased risk 
of complications in routine clinical practice. It would be prudent 
to exercise caution in those with an increased background risk of 
aspiration, such as the elderly.
disease-specific quality standards
The length of a Barrett’s segment should be classified according 
to the Prague classification.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
The Prague classification describes the maximal length and 
the circumferential extent of the Barrett’s segment, measured 
Figure 2 A schematic demonstrating the recommended stations for photo-documentation during a diagnostic oesophago-gastro-
duodenoscopy. (Reproduced with permision from Thieme [43])
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on withdrawal of the endoscope.83 This classification has been 
widely adopted, with good interobserver agreement.84–87 This 
method of universal reporting means that patients can be strati-
fied according to risk, with their follow-up interval determined 
in line with existing guidelines.86 This may also assist in deter-
mining appropriately timed procedure slots for particularly long 
segments.
Where a lesion is identified within a Barrett’s segment, this 
should be described using the Paris classification and targeted 
biopsies taken.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Lesions identified within a Barrett’s segment should be consid-
ered suspicious until proved otherwise. These should be charac-
terised according to the Paris classification, with their location 
described by distance from the incisors and clock face position. 
Targeted biopsy specimens should be taken. Where there is doubt 
as to the nature of a lesion, multidisciplinary team discussion or 
referral to a specialist centre may be warranted.
When no lesions are detected within a Barrett’s segment, 
biopsies should be taken in accordance with the Seattle protocol.
Level of agreement: 90%
Grade of evidence: moderate
Strength of recommendation: strong
Dysplasia within a Barrett’s segment may not always be 
visible.88 It has been shown that adherence to systematic biopsy 
protocol throughout the normal appearing mucosa is associated 
with a greater detection of dysplastic change.89–93 The Seattle 
protocol involves sampling the Barrett’s segment with quadrantic 
biopsy specimens taken at 2 cm intervals. Where suspicious areas 
are identified, these should be imaged and biopsied before the 
acquisition of non-targeted biopsy specimens. The role for 
advanced imaging is controversial, but, where available, it can 
be employed in an attempt to improve lesion detection and char-
acterisation.86
If squamous neoplasia is suspected, full assessment with 
enhanced imaging and/or Lugol’s chromo-endoscopy is required.
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
Squamous cell oesophageal cancer accounts for more than a 
quarter of all oesophageal malignancies.94 While lesions may 
be difficult to visualise with white light endoscopy alone, it has 
been well established that Lugol’s iodine can aid the detection 
of dysplastic lesions. This dye is taken up by glycogen, with 
dysplastic areas relatively glycogen deplete and therefore Lugol 
void. Suspicious areas appear pale on a dark brown background, 
before fading to a pink discolouration.95–99 In order to pick 
up lesions, we would advocate controlled scope withdrawal, 
inspecting the full length of the oesophagus. Emerging studies 
propose narrow band imaging as an alternative to Lugol’s chro-
mo-endoscopy. These are encouraging but are yet to be tested in 
community settings.100–103 Where appropriate imaging cannot be 
performed locally, referral to a specialist centre is required.
Oesophageal ulcers and oesophagitis that is grade D or atyp-
ical in appearance, should be biopsied, with further evaluation 
in 6 weeks after proton pump inhibitor therapy.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
An observed oesophageal ulcer, defined as a discrete break in 
the oesophageal mucosa measuring at least 5 mm in diameter, 
should be described, with the ulcer edge biopsied. A repeat 
OGD to ensure ulcer healing should be performed 6 weeks later, 
after high-dose proton pump inhibitor therapy.104 Similarly, 
where severe oesophagitis is seen, defined as grade D according 
to the Los Angeles classification,105 biopsy specimens should be 
taken to exclude underlying dysplasia. In the absence of contra-
indications a repeat OGD should be performed in 6 weeks to 
exclude underlying malignancy or Barrett’s oesophagus.
The presence of an inlet patch should be photo-documented.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: weak
Heterotopic gastric mucosa proximally within the oesoph-
agus, commonly known as a cervical inlet patch, has a preva-
lence of approximately 3% in those undergoing OGD.106–109 The 
clinical significance of this finding is unclear, although it may 
be associated with an increased frequency of reflux, globus and 
dysphagia, with several small studies suggesting ablation may 
result in symptomatic improvement.110–112
Several case reports have demonstrated the presence of 
dysplastic mucosa within inlet patches, with an estimated inci-
dence of malignancy of 0–1.6%.113–116 While biopsies are helpful 
to confirm the diagnosis and exclude dysplasia, an inlet patch 
should not be considered to be a premalignant condition, and 
there is no evidence to support the acquisition of routine biop-
sies or surveillance where dysplasia is not found.
Detection of an inlet patch can be used as a surrogate maker 
of a thorough examination of the oesophagus. As these are most 
commonly noted just below the upper oesophageal sphincter, an 
inlet patch can be easily overlooked when rapidly withdrawing 
the endoscope. Use of narrow band imaging can increase the 
detection of an inlet patch threefold.117 118
The presence of a hiatus hernia should be documented and 
measured.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: weak
There are four types of hiatus hernia, with the sliding hiatus 
hernia accounting for 95% of cases.119 A hernia can be diagnosed 
endoscopically by establishing that the distance between the top 
of the gastric folds and the diaphragmatic pinch is ≥2 cm. These 
measurements are subject to peristalsis, air insufflation and may 
be difficult to measure accurately in the presence of Barrett’s 
oesophagus.120 121 A hiatus hernia is best inspected while in 
retroflexion, allowing for the assessment of both hiatal size and 
integrity of the oesophagogastric junction (OGJ).122
Biopsies from two different regions in the oesophagus should 
be taken to rule out eosinophilic oesophagitis in those presenting 
with dysphagia/food bolus obstruction, where an alternate cause 
is not found.
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
Eosinophilic oesophagitis (EO) is an immune-mediated 
condition, characterised by eosinophilic infiltration of the 
oesophageal mucosa. Diagnosis is confirmed on histology, 
where ≥15 eosinophils per high power field are detected.123 
While EO is an increasingly diagnosed phenomenon, data 
from population registers suggest an increased incidence and 
this is not merely due to increased awareness.124 125 Patients 
typically present with dysphagia or food bolus obstruction. 
While the characteristic endoscopic findings of tracheali-
sation, white patches, linear furrows and strictures are well 
described, appearance may be normal in as manay as 15% of 
sufferers.126–132
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Eosinophils are not equally distributed throughout the 
oesophagus and therefore a false-negative result due to 
sampling error is possible.133 134 Additionally, diagnostic yield 
is related to the number of biopsies taken. A single biopsy has 
a sensitivity of 55%, which increases to close to 100% when 
six biopsies are taken.134–137 Given that endoscopy can be 
normal in the presence of EO, we recommend that a total of 
six biopsies are taken with samples acquired from at least two 
areas of the oesophagus (lower, mid or upper third), in those 
presenting with dysphagia where no alternative cause has been 
identified.
Varices should be described according to a standardised clas-
sification.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Oesophagogastric varices are the most significant of the collat-
erals produced as a consequence of increased portal pressure, 
posing a risk of rupture and life-threatening bleeding. Endos-
copy is the most accurate method for the assessment of varix 
size, although grading is subject to interobserver variation.138 
Several different classification systems exist. Clinically, differen-
tiation between small and large varices is the most important 
distinction to make, as this offers the opportunity for prophy-
lactic measures to reduce bleeding risk.139 140 It is recommended 
that varices are classified according to their size, as grade 1, 2 or 
3, in accordance with existing guidelines.138
Strictures should be biopsied to exclude malignancy before 
dilatation.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: weak
Strictures, when first encountered, should not be dilated 
before histology is obtained to exclude malignancy.141–143 
Although it is often possible to determine the nature of a stric-
ture endoscopically, there is a small, theoretical, but unaccept-
able risk of converting a localised tumour into disseminated 
disease should a malignant stricture perforate secondary to endo-
scopic therapy.144 This approach also facilitates diagnosis of the 
underlying pathology and optimal non-endoscopic therapy—for 
example, acid suppression for peptic strictures. This approach 
may not be necessary where there is an established underlying 
benign aetiology, such as eosinophilic oesophagitis, peptic ulcer-
ation, or previous treatment, such as endoscopic mucosal resec-
tion or radiofrequency ablation.
Gastric ulcers should be biopsied and re-evaluated after 
appropriate treatment, including H. pylori eradication where 
indicated, within 6–8 weeks.
Level of agreement: 90%
Grade of evidence: weak
Strength of recommendation: strong
Where a gastric ulcer is seen during an OGD, this should 
be fully assessed, including a description of the size and loca-
tion.145 146 Helicobacter pylori status should be assessed by a 
rapid urease test or gastric biopsies, and if appropriate, eradi-
cation therapy should be prescribed.147 A repeat OGD to ensure 
that the ulcer has healed should be performed 6–8 weeks after 
the index OGD.148–152
Where there are endoscopic features of gastric atrophy or 
intestinal metaplasia separate biopsies from the gastric antrum 
and body should be taken.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: weak
Perhaps owing to a relatively low incidence of gastric cancer in 
the UK, surveillance of premalignant gastric change is not estab-
lished. Gastric atrophy and intestinal metaplasia are thought to 
give rise to gastric cancer through the inflammation–metaplasia–
dysplasia–carcinoma pathway.153 154 Where endoscopic features 
suggest potential gastric atrophy or metaplasia, representative 
biopsies should be taken to confirm this diagnosis and to exclude 
dysplasia. Histological change may be patchy and so the Sydney 
protocol advocates the acquisition of two non-targeted biopsies 
from the antrum and body and one from the incisura as separate 
samples, in addition to targeted biopsies of any visible lesions.155 
Careful examination of the stomach with white light endoscopy 
should be performed as a minimum, with evaluation with chro-
moendoscopy considered. Where H. pylori is present, this should 
be eradicated, with evidence suggesting that this may cause a 
degree of regression of atrophy and delay the progression of 
intestinal metaplasia.156–159 The surveillance of intestinal meta-
plasia remains controversial, current ESGE guidelines suggest 
that 3-yearly surveillance should offered to patients, especially 
those with a family history or risk factors.155 160 161
Where iron deficiency anaemia is being investigated, separate 
biopsies from the gastric antrum and body should be taken, as 
well as duodenal biopsies if coeliac serology is positive or has 
not been previously measured.
Level of agreement: 80%
Grade of evidence: weak
Strength of recommendation: weak
Iron deficiency anaemia has been found to be associated 
with gastric atrophy. We suggest biopsies are taken from the 
gastric antrum and body to confirm this diagnosis and avoid 
further unnecessary investigations. Biopsies from the duodenum 
should also be taken if coeliac serology is positive or has not 
been measured before an OGD performed for iron deficiency 
anaemia.
Where gastric or duodenal ulcers are identified, H. pylori 
should be tested and eradicated if positive.
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
Where gastric or duodenal ulcers are observed, H. pylori should 
be excluded by a rapid urease test or gastric biopsies.147 162–164 
Medication history should be reviewed to exclude contributory 
pharmacological agents such as non-steroidal anti-inflammatory 
drugs.165 166 There is no role for the surveillance of duodenal 
ulcers, with repeat OGD having a low diagnostic yield.
The presence of gastric polyps should be recorded, with the 
number, size, location and morphology described, and represen-
tative biopsies taken.
Level of agreement: 100%
Grade of evidence: moderate
Strength of recommendation: strong
The presence, number and size of any detected gastric polyps 
should be documented. It is recommended that the actual number 
of polyps is recorded where there are five or less; however, it is 
acceptable where there are more than five to use the description 
of multiple polyps. All atypical polyps should be described. The 
majority of gastric polyps are accounted for by fundic gland and 
hyperplastic polyps.167–169 Although fundic gland polyps can be 
predicted with a high degree of accuracy based on endoscopic 
appearances, biopsies are recommended to confirm the histo-
logical diagnosis and exclude dysplasia.170 171 A single biopsy 
of a polyp is usually sufficient, with this approach having been 
found to be as accurate as polypectomy in 97.3% of cases.172 
Repeat biopsies of a previously diagnosed benign gastric polyps 
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are not indicated.171 Where there are multiple polyps, represen-
tative biopsies should be taken, as it is known that coexisting 
polyps are usually of the same histological type.173 Premalignant 
polyps should undergo surveillance in accordance with existing 
guidelines, while some dysplastic polyps should be considered 
for removal.171
It should be noted that approximately 30–50% of patients with 
familial adenomatous polyposis have adenomas in the stomach 
and up to 90% in the duodenum.174 175 Often these patients have 
a carpet of fundic gland polyps in the proximal stomach making 
it technically challenging to identify the adenomatous change.175 
The diagnosis and surveillance of familial adenomatous polyp-
osis in the UGI tract should follow in accordance with published 
guidelines.174.
Where coeliac disease is suspected, a minimum of four biop-
sies should be taken, including representative biopsies from the 
second part of the duodenum and at least one from the duodenal 
bulb.
Level of agreement: 100%
Grade of evidence: strong
Strength of recommendation: strong
Coeliac disease is an autoimmune condition, characterised 
by gluten-induced small bowel villous atrophy. Classic endo-
scopic features of flattened mucosal appearance, nodularity, a 
reduction in duodenal folds and scalloping have been described. 
Coeliac disease may be present in the absence of endoscopic 
features and therefore biopsies to obtain a histological diag-
nosis where there is a suspicion of coeliac disease are recom-
mended.176–179 Villous atrophy may occur in a patchy distribu-
tion and so in order to optimise diagnosis a minimum of four 
biopsies taken at different locations throughout the duodenum, 
including the bulb, are required.180–184 Where an OGD is being 
performed specifically to obtain histological confirmation of 
coeliac disease, patients should adhere to a gluten-rich diet to 
avoid a false-negative result, consuming gluten in more than 
one meal a day for at least 6 weeks.185 Once a diagnosis has been 
established, management should be in accordance with existing 
guidelines.182 185
A malignant looking lesion should be photo-documented and 
a minimum of six biopsies taken.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
A standardised approach to reporting malignant lesions 
enables the planning of potential endoscopic therapy and, where 
this is not possible, this may guide surgical or palliative measures. 
As a minimum, a report should describe the anatomical location, 
including the distance from a fixed landmark, (eg, from the inci-
sors), number, size and morphology of any lesions as well as any 
abnormalities of the background mucosa.
There is little evidence for the optimal number of biopsies 
required to ensure a diagnosis where malignancy is present.186 187 
Accepted convention is to obtain at least six representative biop-
sies of the lesion in question. This would appear to be an appro-
priate number given the biopsy protocols used for other patholo-
gies of the gastrointestinal tract and in view of the importance of 
establishing a prompt diagnosis of malignancy without the need 
for repeated examinations. In addition to confirming a diag-
nosis, it may be necessary to obtain sufficient tissue to perform 
additional techniques, which may influence treatment options, 
such as HER2 testing.188–190 Acquisition of fewer biopsies may 
need to be considered in individual patients—for example, those 
who are being anticoagulated, those with bleeding diathesis, or 
on the basis of lesion characteristics.
Methods for early escalation of malignant lesions to an upper 
gastrointestinal multidisciplinary team meeting should be in 
place. This will usually be in the form of a team to which an 
endoscopist can refer a patient following the detection of a 
potentially malignant lesion.
postprocedure quality standards
After OGD readmission, mortality and complications should be 
audited.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Complications related to the procedure or associated with the 
use of sedation should be audited annually. Units should record 
the 8-day readmission rate and 30-day mortality after OGD in 
accordance with standards set out byJAG.3 After a procedure 
verbal and written instructions should be given to patients, with 
advice about when, where and how to seek medical attention if 
required. 3
A report summarising the endoscopy findings and recommen-
dations should be produced and the key information provided to 
the patient before discharge.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
A report describing the main findings of the OGD and key 
recommendations should be produced contemporaneously. This 
should include the extent of the examination, any abnormal 
findings, documentation of any samples taken and the proposed 
management plan, including the need for any further endoscopy 
or imaging.191–193 Where surveillance is required—for example, 
in Barrett’s oesophagus, the recommended interval should be 
specified. Any instructions to the patient about changes in medi-
cation, pending results or follow-up should be recorded. Where 
appropriate, the patient should be offered a copy of the written 
report, with an opportunity to ask questions. This report should 
be made available to the referring physician and GP within 
24 hours. Where an endoscopy has taken place outside of the 
endoscopy department or out of hours, a written report in the 
patient notes is sufficient until an official report can be issued at 
the earliest time practical.
A method for ensuring histological results are processed must 
be in place.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
Histology results taken during endoscopic procedures should 
be promptly reviewed.3 Where an unsuspected case of high-
grade dysplasia or malignancy is detected on histological review, 
this should also be highlighted to the relevant multidisciplinary 
team by the histopathologist.
Endoscopy units should audit rates of failing to diagnose 
cancer at endoscopy up to 3 years before an oesophago-gastric 
cancer is diagnosed.
Level of agreement: 100%
Grade of evidence: weak
Strength of recommendation: strong
An UGI cancer detected within 3 years of an OGD should be 
considered as a failure to diagnose the cancer earlier (termed 
post OGD UGI cancer or POUGIC). Retrospective studies have 
shown that the rate of POUGIC ranges between 4.6% and 
14.4%.4 6 194–197 We recommend that units audit performance data 
to ensure that POUGIC rates do not exceed 10% and a root cause 
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analysis of factors contributing to individual cases is performed. 
We suggest that this evaluation is performed every 3 years, in order 
to have sufficient POUGIC cases to compare against the set stan-
dard. Prospective collection of this data at the point of a patient’s 
referral to an UGI multidisciplinary team may be a practical way of 
ensuring these data are collected.
conclusIons
It is hoped that with the institution of the above recommendations 
there will be a focus on improving quality in diagnostic UGI endos-
copy. Key performance indicators have been determined from the 
above recommendations (figure 2), which should be instituted, 
measured and audited within departments. Improvement will be 
confirmed by an increased rate of early detection of neoplasia and 
a reduced incidence of interval cancers.
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